![Chris Heymans](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Origen de la red de primer grado Chris Heymans.
Entidad | Tipo de entidad | Industria | |
---|---|---|---|
Biocartis SA
![]() Biocartis SA Medical SpecialtiesHealth Technology Biocartis SA develops molecular diagnostic solutions. It focuses on Oncology. The firm’s products include Idylla and Oncology assays and mutation tests. It also provides instant access to personalized medicine for patients. The company was founded by Rudi Pauwels in 2007 and is headquartered in Lausanne, Switzerland.
23
| Subsidiary | Medical Specialties | 23 |
Gráfico Empresas conectadas de segundo grado
Relaciones con varias empresas
Empresas conectadas a Chris Heymans a través de su red personal
Empresa | Sector | Personas relacionadas | Puesto principal |
---|---|---|---|
BIOCARTIS GROUP NV | Medical Specialties | Director/Board Member Director/Board Member Chairman Chief Executive Officer Director/Board Member Chief Executive Officer Director/Board Member Director/Board Member Director/Board Member Director/Board Member Chief Tech/Sci/R&D Officer Chief Operating Officer Director/Board Member | |
Ghent University | College/University | Undergraduate Degree Graduate Degree Graduate Degree Graduate Degree Graduate Degree Doctorate Degree | |
Katholieke Universiteit Leuven | College/University | Graduate Degree Doctorate Degree Doctorate Degree Graduate Degree Graduate Degree Graduate Degree | |
MDXHEALTH SA | Medical Specialties | Director/Board Member Director/Board Member Director/Board Member Director/Board Member Chairman | |
MyCartis NV
![]() MyCartis NV BiotechnologyHealth Technology MyCartis NV develops technologies for healthcare personalization needs. It offers Evalution, a multiplex analysis platform to develop protein and nucleic-acid based clinical biomarkers. The company provides disruptive solutions in the fields of clinical and translational research for various applications in the detection of proteins and nucleic acids, such as sandwich immunoassays, antibody assays, genotyping assays, and mutation analysis assays to customers and partners. It offers products for various disease areas, including cell signalling, cardiovascular, oncology, and preeclampsia. The company was founded by Koen Kas in August 2004 and is headquartered in Ghent, Belgium. | Biotechnology | Director/Board Member Chief Executive Officer Director/Board Member Director/Board Member | |
University of Antwerp | College/University | Graduate Degree Graduate Degree Graduate Degree | |
ABLYNX | Biotechnology | Director/Board Member Director/Board Member Corporate Officer/Principal | |
Intrexon ActoBiotics NV
![]() Intrexon ActoBiotics NV BiotechnologyHealth Technology Intrexon ActoBiotics NV manufactures biopharmaceutical products. It focuses on the development and commercialization of a new generation of biological drugs. The company represents a novel concept for oral administration of therapeutic proteins, and is designed to be safer and more effective than injectable biopharmaceuticals. Intrexon Actobioticswas founded by Mark Vaeck, Emil Pot and Bernard Coulie in June 2006 and is headquartered in Zwijnaarde, Belgium. | Biotechnology | Director/Board Member Director/Board Member Chairman | |
deVGen NV
![]() deVGen NV BiotechnologyHealth Technology deVGen NV provides biotechnology services for the pharmaceutical and agrochemical industries. It innovates in crop protection research and environment induced stress tolerance for its own crops and provides technology to corporate partners. The firm produces and sells its hybrid seeds in field crops such as rice, sunflower, sorghum and pearl millet in the Indian subcontinent and Southeast Asia. The company was founded by Thierry Bogaert on September 10, 1997 and is headquartered in Ghent, Belgium. | Biotechnology | Director/Board Member Director of Finance/CFO Director/Board Member | |
Fujirebio Europe NV
![]() Fujirebio Europe NV Medical SpecialtiesHealth Technology Fujirebio Europe NV develops and markets diagnostic products to improve therapy management and patient health. It focuses on molecular diagnostics and multiparameter testing. The firm also provides LUMIPULSE G1200, an automated chemiluminescent enzyme immunoassay system; LUMIPULSE G600 II, an automated benchtop CLEIA system, routine and novel markers for the oncology sector. The company was founded in 1985 by Philippe Leboulch and is headquartered in Ghent, Belgium. | Medical Specialties | Founder Corporate Officer/Principal Chief Tech/Sci/R&D Officer | |
FlandersBio vzw
![]() FlandersBio vzw Miscellaneous Commercial ServicesCommercial Services FlandersBio vzw is a life sciences cluster organization based in Flanders, Belgium. FlandersBio creates value by organizing networking and training activities, supporting internationalization, providing services, and building expertise. The Belgian company was founded by Jean Marie Stassen. | Miscellaneous Commercial Services | Director/Board Member Director/Board Member Chairman | |
Antelope Dx BV
![]() Antelope Dx BV Packaged SoftwareTechnology Services Antelope Dx BV develops a point-of-need diagnostics platform that provides patients, consumers, and healthcare professionals with on-the-spot access to key health parameters. The private company is based in Ghent, Belgium. The Belgian company was founded in 2019 by Jan-Willem Hoste and Hilde Windels. Hilde Windels has been the CEO since 2019. | Packaged Software | Director/Board Member Founder | |
Vlaams Instituut voor Biotechnologie - Flanders Institute
![]() Vlaams Instituut voor Biotechnologie - Flanders Institute Other Consumer ServicesConsumer Services Vlaams Instituut voor Biotechnologie - Flanders Institute operates as a non-profit organization, provides research and development services. It specializes in translating basic scientific results into pharmaceutical, agricultural and industrial applications. The company was founded on January 1, 1996 and is headquartered in Ghent, Belgium. | College/University | Director/Board Member Director/Board Member | |
Advent Venture Partners LLP
![]() Advent Venture Partners LLP Investment ManagersFinance Advent Venture Partners LLP (AVP) is a private equity/venture capital firm founded in 1981 by David James Scott Cooksey. The firm is headquartered in London, United Kingdom. | Investment Managers | Private Equity Investor Private Equity Investor | |
GALAPAGOS NV | Biotechnology | Chairman Founder | |
Fortino Capital Partners NV
![]() Fortino Capital Partners NV Investment ManagersFinance Fortino Capital Partners NV is a venture capital and private equity firm founded in 2013 by Duco W. Sickinghe and Renaat Berckmoes. The firm is headquartered in Antwerp with additional office in Amsterdam. | Investment Managers | Founder | |
Dr. Reddy's Research & Development BV
![]() Dr. Reddy's Research & Development BV Pharmaceuticals: MajorHealth Technology Dr. Reddy's Research & Development BV is engaged in the development and manufacture of injectable pharmaceutical products. It provides formulation, development, drug delivery, and clinical material manufacturing services to biotech and pharmaceutical companies worldwide. The company was founded by Joost J. M. Holthuis on July 20, 1995 and is headquartered in Leiden, Netherlands. | Pharmaceuticals: Major | Chairman | |
Savaco NV
![]() Savaco NV Information Technology ServicesTechnology Services Savaco NV engages in the provision of information technology solutions. It offers hybrid data centers, flexible workplaces, computer-aided design, product lifecycle management, and business productivity services. The company was founded by Rick Vandemoortele and Carl Sabbe on February 4, 1991 and is headquartered in Kortrijk, Belgium. | Information Technology Services | Director/Board Member | |
Het Vlaams Parlement | Corporate Officer/Principal | ||
Johnson & Johnson Innovation - JJDC, Inc.
![]() Johnson & Johnson Innovation - JJDC, Inc. Investment ManagersFinance Johnson & Johnson Innovation JJDC Inc (Johnson & Johnson Innovation JJDC) is a venture capital subsidiary of Johnson & Johnson founded in 1973. The firm is headquartered in New Brunswick, New Jersey. | Investment Managers | Corporate Officer/Principal | |
DoseVue NV
![]() DoseVue NV Medical SpecialtiesHealth Technology DoseVue NV is developing innovative technologies for convenient and accurate in-vivo dosimetry. It offers DoseWire Series 100 & DoseWire Series 200. The company was founded by Emiliano D Agostino in March 2013 and is headquartered in Turnhout, Belgium. | Medical Specialties | Chairman | |
SFPI-FPIM SA/NV
![]() SFPI-FPIM SA/NV Financial ConglomeratesFinance Société Fédérale de Participations et d’Investissement SA operates as a state-owned investment company. It engages in investments in public and private companies in economic and cross-cutting sectors such as sustainable development, innovation, airport and aviation, real estate, and ageing of the population. The company was founded on November 1, 2006 and is headquartered in Brussels, Belgium. | Financial Conglomerates | Director/Board Member | |
DeuterOncology SA
![]() DeuterOncology SA BiotechnologyHealth Technology DeuterOncology SA is a Belgian preclinical-stage biotechnology company that specializes in developing targeted cancer therapies. DeuterOncology is based in Liege, BE. The company's focus is on creating a first-in-class dual MET and RAS pathway inhibitor. The company was founded in 2020 by Timothy Perera, who has been the CEO since 2020. | Biotechnology | Chairman | |
TELENET GROUP HOLDING NV | Major Telecommunications | Director of Finance/CFO | |
PRIMACOM AG | Cable/Satellite TV | Director/Board Member | |
Chroma Therapeutics Ltd.
![]() Chroma Therapeutics Ltd. BiotechnologyHealth Technology Chroma Therapeutics Ltd. engages in the discovery and development of therapies for the treatment of cancer and inflammation. It focuses on the discovery and development of novel small molecule drugs based upon chromatin biology and novel cell accumulation approaches. The firm uses chromatin biology, drug accumulation approaches to discover and develop cancer, inflammation treatments and small molecule drugs. The company was founded by David Allis, Alan Hornsby Davidson, Alan Hastings Drummond, Anthony Kouzarides and Paul Workman in September 2001 and is headquartered in Abingdon, the United Kingdom. | Biotechnology | Chairman | |
Janssen Pharmaceutica NV
![]() Janssen Pharmaceutica NV Pharmaceuticals: MajorHealth Technology Janssen Pharmaceutica NV engages in the development of medical solutions. It offers research and development services in the field of mental illness, neurological disorders, anesthesia, analgesia, gastrointestinal disorders, fungal infection, allergies and cancer. The firms products include Zytiga, Caelyx, Dacogen, Edurant, Fentanyl-Janssen, Intelence, Leustatin, , Pariet, and Reminyl. The company was founded in 1953 by Paul Janssen and is headquartered in Beerse, Belgium. | Pharmaceuticals: Major | Chief Executive Officer | |
Vivactis NV | Miscellaneous | Director/Board Member | |
Benaruca SA | Miscellaneous | Chairman | |
Asuragen, Inc.
![]() Asuragen, Inc. Medical SpecialtiesHealth Technology Asuragen, Inc. develops molecular diagnostic products. Its products include AmplideX and QuantideX. It uses genomics to drive patient management through clinical testing solutions. The company was founded in March 2006 by Matthew M. Winkler and is headquartered in Austin, TX. | Medical Specialties | Chief Tech/Sci/R&D Officer | |
EXAGEN INC. | Medical/Nursing Services | Chief Tech/Sci/R&D Officer | |
Abbott Diagnostics, Inc.
![]() Abbott Diagnostics, Inc. Medical SpecialtiesHealth Technology Abbott Diagnostics, Inc. develops, manufactures and sells medical diagnostic instrument, test and automation products. The company is headquartered in Santa Clara, CA. | Medical Specialties | Corporate Officer/Principal | |
Université Catholique de Louvain | College/University | Doctorate Degree | |
RespiVert Ltd.
![]() RespiVert Ltd. Medical DistributorsDistribution Services RespiVert Ltd. operates as a small molecule drug discovery company. The firm develops small-molecule inhaled therapies for the treatment of chronic obstructive pulmonary disease (COPD), asthma, and cystic fibrosis. The company was founded by William Garth Rapeport, Peter Strong, Kazuhiro Ito, John Murray and Peter Barnes in 2007 and is headquartered in London, the United Kingdom. | Medical Distributors | Chairman | |
Tibotec Virco NV
![]() Tibotec Virco NV Miscellaneous Commercial ServicesCommercial Services Tibotec-Virco NV develops drugs and individualized disease management products. The firm also offers early stage research programs concentrating on the development of treatments for cancer, hepatitis C, and other infectious diseases. The company also provides HIV drug resistance testing and other analytical services in the United States, Japan, Europe, Canada, and Australia. It has operations in Belgium, North Carolina, Ireland, and the United Kingdom. It was founded in by Paul Stoffels in March, 2001 and is headquartered in Mechelen, Belgium. | Miscellaneous Commercial Services | Chief Executive Officer | |
Valetusan Ltd.
![]() Valetusan Ltd. Miscellaneous Commercial ServicesCommercial Services Valetusan Ltd. is an Irish private company located in Dublin that provides business and management consultancy services. | Miscellaneous Commercial Services | Director/Board Member | |
Cambenes SA | Director/Board Member | ||
Riverwells Investments SA | Director/Board Member | ||
Calimontes SL | Director/Board Member | ||
Caruso Inversiones SL | Director/Board Member | ||
Smile Invest Management Co. NV
![]() Smile Invest Management Co. NV Investment ManagersFinance Smile Invest Management Co. NV (Smile Invest) is a private equity firm founded in 2017 by Urbain Vandeurzen. The firm is headquartered in Linden. | Investment Managers | Private Equity Investor | |
ANeuroTech
![]() ANeuroTech Miscellaneous Commercial ServicesCommercial Services ANeuroTech is a Belgian mental health company that specializes in developing innovative treatments with minimal or no side effects. ANeuroTech is located in Belgium. The private company's lead asset, ant-01, is an adjunctive anti-depression drug that has shown positive results in late-stage clinical trials. The drug is a low-dose of an existing substance, pipamperone dihydrochloride, and has an excellent safety profile. ANeuroTech plans to begin a pivotal phase iiib clinical trial of ant-01 as an adjunctive anti-depression drug for major depressive disorder (MDD) in 2023. The company was founded by CEO Dr. Erik Buntinx, an experienced clinician and key opinion leader in the field. | Miscellaneous Commercial Services | Chairman |
Estadísticas
Internacional
Bélgica | 36 |
Estados Unidos | 5 |
Reino Unido | 4 |
Luxemburgo | 4 |
España | 3 |
Sectorial
Health Technology | 20 |
Commercial Services | 8 |
Consumer Services | 7 |
Finance | 7 |
Technology Services | 3 |
Operativa
Director/Board Member | 150 |
Corporate Officer/Principal | 36 |
Chairman | 28 |
Independent Dir/Board Member | 27 |
Chief Executive Officer | 23 |
Las relaciones más conectadas
Insiders | |
---|---|
Raj Bhikhu Parekh | 50 |
Rudi Mariën | 31 |
Staf van Reet | 22 |
Rudi Pauwels | 19 |
Hilde Windels | 18 |
Ruth Devenyns | 18 |
Domenico Valerio | 15 |
Peter Piot | 14 |
Thomas Wayne Gibbs | 11 |
Christine Deuschel Cornioley | 10 |
Renaat Berckmoes | 9 |
Mark Shaffar | 7 |
Clark Harrison | 6 |
Joost N. Schellens | 6 |
Erwin Sablon | 6 |
- Bolsa de valores
- Insiders
- Chris Heymans
- Conexiones Empresas